Infusion of PD1/PDL1/CTLA4 Inhibitors Via Hepatic Arterial for Immunotherapy of Hepatocellular Carcinoma

This trial was designed to investigate the survival outcomes, response rates, and safety of patients with Barcelona-Clinical Hepatocellular Carcinoma (BCLC)-C-stage liver cancer by hepatic artery versus vein infusion of PD1/PDL1/CTLA4 inhibitor or their combinations.

Trial Details

NCT ID

NCT03949231

Phase

PHASE3

Sponsor

Second Affiliated Hospital of Guangzhou Medical University

Status

RECRUITING

Cancer Type

Hepatocellular Carcinoma (HCC) Liver Cancer

Interventions

PD1/PDL1 inhibitor

Locations (sample)

Guanzhou, Guangdong, China|23.06828,113.37117

Key Eligibility Criteria

Cytohistological confirmation is required for diagnosis of HCC.、
Signed informed consent before recruiting
Age between 18 to 80 years with estimated survival over 3 months.
Child-Pugh class A or B/Child score \> 7; ECOG score \< 2

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Hepatocellular Carcinoma (HCC) Liver Cancer Trials on Trialify →